Risk Stratification and MRD-driven Maintenance for MM After ASCT

Patients who are R2-ISS 3 or 4 OR MRD (Minimal Residual Disease) positivity will receive daratumumab plus lenalidomide maintenance.

"Patients are R2-ISS 1,2 and MRD (Minimal Residual Disease) negative after autologous stem cell transplantation.~Patients will receive the single drug lenalidomide maintenance."